Identifying life science breakthroughs to address unmet clinical needs, we invest in translational medicine frontiers to capture China opportunities.
Positioning
Alwin Capital is a leading venture capital in China specializing in early stage life science investments. Driven by theme-focused research in life science, Alwin Capital has developed investment strategies that capture outstanding opportunities for innovative diagnostic and therapeutic developments. We are committed to the long-term investment in life science with the pursuit of the excess investment return based on the scientific insights.
Founded in 2015, Alwin Capital was formed by former CICC senior executives, bringing in decades of experience in healthcare research and medical markets. Alwin Capital currently manage three venture funds with more than RMB 1 Billion in AUM, having invested in dozens of companies in life science and cultivated a bunch of leading companies in respective segments.
Portfolio
Over the past two decades, life science discoveries have been transformed into clinical applications and solutions, revealing a whole new horizon for healthcare industries. In the theme line based on gene sequencing, the industrial chain of molecular diagnosis has developed in an all-round way. In the theme line based on gene synthesis, drug research and development has entered the macromolecular platform from the small molecular platform, and then entered the living drug platform. In the theme line based on gene editing, new clinical technologies such as gene therapy have infiltrated the real clinical scenario. At the same time, life science, driven by artificial intelligence technology, has stepped a new development stage of digital life and precision medicine.
Under the current background of the development of life science and clinical medicine, adhering to the professional investment research in life science and the profound understanding of portfolio management, Alwin Capital has formed a systematic investment layout covering Innovative Drugs, Molecular Diagnostics, Innovative Hardware, Scientific Services and AI Applications.
Incubated and invested by Alwin, Immorna is one of the most promising mRNA Innovative drug development company in China.
Gene Therapy-Hui-Gene
Hui-Gene Therapeutics is an innovative gene therapy company based on both AAV platform and CRISPR technology.
Intestinal Microbiome-Xbiome
Xbiome is the only microbiome drug R&D company in China with global leading progress and advancement.
Complement Drugs-Kira Pharm
Kira Pharm is a global complement drug R&D company founded by a world leading scientist in the field of complement system.
ADC Drugs-Bliss-Bio
Bliss-Bio focuses its pipeline on ADC drugs with a seasoned management team with impressive track records and execution capabilities.
Cell Therapy-Uni-CAR
Uni-CAR is a CAR-T company that has the most clinical trials in China with an industrial GMP certified cell preparation and manufacturing facilities.
O/I Drugs-Adlai Nortye
Adlai Nortye is an onco-immunology drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.
Cancer Liquid Biopsy-Genecast
Genecast is the leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis
Mass Spectrometry Testing-Yingsheng Biology
Yingsheng Biology is a leading player in mass spectrometry testing market with a pipeline covering key products in China.
Genetic Disease Testing-Chigene
Chigene is the China market leader in genetic disease testing with the largest database of genetic disease patients.
Molecular Pathology Platform-Geneis:
Geneis is a multi-platform molecular pathology service provider to hospitals with comprehensive capabilities.
DTC Gene Testing-23 MoFang
23 MoFang is the No. 1 DTC gene testing player and accounts for 40% of market share in China.
Forensic DNA Testing-SuperBio
SuperBio is the leader in forensic DNA testing with patented technologies and devices in China.
ONT Nanopore Sequencing-Qitan Tech
Qitan Tech is an innovative hardware R&D company in the area of ONT nanopore sequencing with the most advanced progress in China.
Micro Droplet Platform-Sniper
Sniper innovated its breakthrough micro droplet generation technology platform, realizing transformation in the field of digital PCR.
Gene Synthesis-Synbio Tech
Synbio Tech is a high- throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies.
The 3rd Generation Gene Sequencing-FraserGen
Frasergen is offering advanced 3rd generation gene sequencing services to scientific research market.
FFR-CT AI Software-Keya Medical
Keya Medical is an AI clinical diagnosis software development company. Its FFR-CT has been approved as the first AI Class III medical device by CFDA.
Radiotherapy AI Software-Datu Medical
Datu Medical provides advanced radiotherapy software in China market. Its radiotherapy sketching software was first approved as the Class III medical device by CFDA.
Dental Invisible Correction-Click:
Clickalign is an innovative company with overall layout of dental invisible orthodontics and digital dental service.
RNA Drugs-Immorna
Incubated and invested by Alwin, Immorna is one of the most promising mRNA Innovative drug development company in China.
Intestinal Microbiome-Xbiome
Xbiome is the only microbiome drug R&D company in China with global leading progress and advancement.
Gene Therapy-Hui-Gene
Hui-Gene Therapeutics is an innovative gene therapy company based on both AAV platform and CRISPR technology.
Complement Drugs-Kira Pharm
Kira Pharm is a global complement drug R&D company founded by a world leading scientist in the field of complement system.
ADC Drugs-Bliss-Bio
Bliss-Bio focuses its pipeline on ADC drugs with a seasoned management team with impressive track records and execution capabilities.
Cell Therapy-Uni-CAR
Uni-CAR is a CAR-T company that has the most clinical trials in China with an industrial GMP certified cell preparation and manufacturing facilities.
O/I Drugs-Adlai Nortye
Adlai Nortye is an onco-immunology drug R&D company with a strong immunotherapy tumor pipeline entering phase III clinical trials.
Cancer Liquid Biopsy-Genecast
Genecast is the leading company in the field of tumor liquid biopsy in China, providing a full solution for tumor companion diagnosis
Mass Spectrometry Testing-Yingsheng Biology
Yingsheng Biology is a leading player in mass spectrometry testing market with a pipeline covering key products in China.
Genetic Disease Testing-Chigene
Chigene is the China market leader in genetic disease testing with the largest database of genetic disease patients.
Molecular Pathology Platform-Geneis:
Geneis is a multi-platform molecular pathology service provider to hospitals with comprehensive capabilities.
Forensic DNA Testing-SuperBio
SuperBio is the leader in forensic DNA testing with patented technologies and devices in China.
DTC Gene Testing-23 MoFang
23 MoFang is the No. 1 DTC gene testing player and accounts for 40% of market share in China.
ONT Nanopore Sequencing-Qitan Tech
Qitan Tech is an innovative hardware R&D company in the area of ONT nanopore sequencing with the most advanced progress in China.
Micro Droplet Platform-Sniper
Sniper innovated its breakthrough micro droplet generation technology platform, realizing transformation in the field of digital PCR.
Gene Synthesis-Synbio Tech
Synbio Tech is a high- throughput gene synthesis company with exploration of in de novo design and synthesis of antibodies.
The 3rd Generation Gene Sequencing-FraserGen
Frasergen is offering advanced 3rd generation gene sequencing services to scientific research market.
FFR-CT AI Software-Keya Medical
Keya Medical is an AI clinical diagnosis software development company. Its FFR-CT has been approved as the first AI Class III medical device by CFDA.
Radiotherapy AI Software-Datu Medical
Datu Medical provides advanced radiotherapy software in China market. Its radiotherapy sketching software was first approved as the Class III medical device by CFDA.
Dental Invisible Correction-Click:
Clickalign is an innovative company with overall layout of dental invisible orthodontics and digital dental service.
Team
Alwin’s founding partners have been working together for nearly ten years, building a strong team culture and mutual trust over the course of their investment careers. They believe in science and the power of research. They all work in the front line to follow their beliefs and principles across their investment process. Strongly supported by a high-profile advisory board from the industry and capital market as well, Alwin is on track to explore and capture the investment opportunities in life science.
